Cytokines

Cytokine is a substance that is made by cells of the immune system. Some cytokines can boost the immune response and others can suppress it. Cytokines can also be made in the laboratory by recombinant DNA technology and used in the treatment of various diseases, including cancer.

What are Cytokines?

The term "cytokine" is derived from a combination of two Greek words - "cyto" meaning cell and "kinos" meaning movement. Cytokines are cell signalling molecules that aid cell to cell communication in immune responses and stimulate the movement of cells towards sites of inflammation, infection and trauma.

Inflammatory Cytokines and Depression

Cytokine Classification

Cytokine Nomenclature

Cytokine Effects

Cytokine Receptors

Latest Cytokines News and Research

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

20 May 2026

Anti-inflammatory drug tocilizumab shows promise for difficult-to-treat depression

Immunotherapy could be a promising new treatment option for patients with difficult-to-treat depression. This is a key finding from a University of Bristol-led pilot randomised controlled clinical trial, published in JAMA Psychiatry today [20 May].

20 May 2026

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

20 May 2026

Biomimetic nanocomposite hydrogel promotes tendon healing and tissue regeneration

The new system, termed KGN@PB@CM, combines several advanced elements. Prussian blue (PB) nanozymes act as potent reactive oxygen species (ROS) scavengers, while kartogenin (KGN)-a small molecule that promotes stem cell migration and tenogenic differentiation-is loaded onto the PB core.

20 May 2026

How antibody-drug conjugates are redefining targeted cancer therapy

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but their success depends on better targets, payloads, linkers, dosing, and patient selection. The Cell review shows that next-generation ADCs could widen treatment options, but safety, resistance, tumor heterogeneity, and clinical translation remain major barriers.

19 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory disease. However, its clinical success is accompanied by a spectrum of immune-related toxicities, which remain a major challenge in practice.

15 May 2026

Researchers develop pH and redox-sensitive systems to reduce immunotherapy toxicity

Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small subset of patients benefit. Many solid tumors remain "cold," characterized by poor immune cell infiltration and resistance to immune checkpoint blockade (ICB).

15 May 2026

New mRNA adjuvant dramatically boosts T-cell vaccine responses in mice

MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines - an advance that could lead to much more powerful cancer vaccines and stronger protection against infectious diseases.

13 May 2026

Rhein protects against intestinal injury in severe acute pancreatitis

Severe acute pancreatitis (SAP) remains one of the most formidable challenges in gastrointestinal emergency medicine.

13 May 2026

Implantable cytokine factories show promise against advanced ovarian cancer

Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step toward clinical reality.

12 May 2026

Tumors exploit peripheral nerves to support cancer growth and spread

Tumors do not communicate only with immune cells, blood vessels, and stromal tissue. A growing body of evidence suggests that cancer can also co-opt the nervous system, reshaping the tumor microenvironment in ways that support growth, invasion, immune escape, and therapeutic resistance.

10 May 2026

Engineered regulatory T cells offer a path toward immunosuppression-free transplants

Organ transplantation remains the cornerstone treatment for end-stage organ failure. While conventional broad-spectrum immunosuppression effectively controls acute rejection, it fails to address chronic rejection and carries long-term side effects including infection, malignancy, and metabolic disorders.

8 May 2026

Food timing may shape how T cells respond to infection and therapy

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic capacity, cytokine production, and persistence after activation. The study identifies triglyceride-rich chylomicrons as key drivers of this effect, suggesting nutritional timing may matter for immune monitoring, vaccination research, and cell-therapy manufacturing.

30 Apr 2026

Antibiotic minocycline shows potential for treating panic disorder symptoms

A study supported by FAPESP shows that small doses of the antibiotic minocycline may help treat panic disorder.

30 Apr 2026

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026

Hepatitis C infection associated with reduced portal insulin levels

Insulin resistance is a common extrahepatic manifestation of hepatitis C virus (HCV) infection (HCVi), but its mechanism is poorly understood.

28 Apr 2026

Natural compound obakulactone shows therapeutic potential for rheumatoid arthritis

A new study published in Engineering reveals that obakulactone (OL), a natural tetracyclic triterpenoid isolated from Phellodendri cortex, exerts a therapeutic effect on rheumatoid arthritis (RA) by promoting the degradation of acyl coenzyme A thioesterase 1 (ACOT1) via the ubiquitin‒proteasome pathway and restoring the homeostasis of unsaturated fatty acids.

25 Apr 2026

Targeting glutamine metabolism enhances CAR-macrophage cancer therapy

Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) exhibit significant metabolic dysregulation, which impairs their antitumor function.

20 Apr 2026